Pharmaceutical company Pfizer is now ready to formally ask the FDA to approve emergency use of its COVID-19 vaccine after the latest trial found a success rate of 95%.

Pfizer said that the study found no meaningful side effects from the vaccine and that it is just as effective for people over the age of 65 as it is for younger people.

One of the people who participated in the trial is Jason Shiffman of Avenel, who says that he volunteered to protect himself and his 88-year-old father who he cares for. He says that he only had mild symptoms after getting the shot.

RELATED: News 12 talks one-on-one with lead investigator for Pfizer COVID-19 vaccine trial

“For about a week or so there were a lot of headaches, redness around the injection site, some nauseousness. But each day it got better and in a week, it cleared up” he says.

Shiffman says he took an antibody test before the vaccine and tested negative. After taking the vaccine, his sample came back positive for antibodies on two separate occasions.

Pfizer expects to produce up to 50 million doses of the vaccine in 2020 and up to 1.3 billion in 2021.